Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17348186 | 0.82 | ADORA2A (0.41) | ADORA2AADORA2BCHRM4BTK | |
| SCHEMBL13106328 | 0.74 | ADORA2A (0.35) | ADORA2AADORA2BCHRM4BTK | |
| SCHEMBL13106332 | 0.74 | L3MBTL1 (0.42) | ADORA2AADORA2BCHRM4 | |
| SCHEMBL13106286 | 0.72 | L3MBTL1 (0.43) | ADORA2AADORA2BCHRM4 | |
| SCHEMBL13106281 | 0.72 | CHRM4 (0.38) | ADORA2AADORA2BCHRM4BTK | |
| SCHEMBL13106185 | 0.69 | CHRM4 (0.39) | ADORA2AADORA2BCHRM4 | |
| SCHEMBL17348190 | 0.69 | NOS3 (0.35) | ADORA2AADORA2BCHRM4BTK | |
| SCHEMBL10151108 | 0.69 | DHFR (0.31) | ADORA2AADORA2BBTK | |
| SCHEMBL13335949 | 0.67 | POLB (0.46) | — | |
| SCHEMBL24393044 | 0.67 | PDE10A (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ADORA2A 1421/4885ADORA2B 2406/4885CHRM4 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.